Author
Reviewer
What has been the impact of COVID-19 on Canadians with cardiovascular disease?
Author | Reviewer |
Shaun Goodman, MD, MSc Co-Director, Canadian VIGOUR Centre, University of Alberta Associate Head, Division of Cardiology, St. Michael's Hospital Toronto, ON |
Milan Gupta, MD, FRCPC, FCCS, CPC(HC) Assistant Professor, Department of Medicine, University of Toronto |
The coronavirus disease 2019 (COVID-19) pandemic has impacted cardiovascular (CV) outcomes and care globally, although to date, there is limited information describing the Canadian experience. In Sweden, which has a publicly supported and widely accessible healthcare system like Canada, COVID-19 has been identified as a risk factor for the subsequent occurrence of acute myocardial infarction (MI) and ischemic stroke, particularly in the first 2 weeks post-infection. The Swedish observations are consistent with previous studies in the pre-COVID-19 era where a transient increase in the risk of MI and stroke has been observed in association with influenza, pneumonia, acute bronchitis, and other chest infections. Thus, in addition to acute CV complications of COVID-19 itself—like myocarditis, pericarditis, decompensated heart failure (HF), and pulmonary embolism—CV implications of the pandemic will likely extend beyond direct, infection-related CV damage.
In England and the United States, several studies have also described significant early decreases in CV testing (e.g., exercise stress tests, echocardiography, nuclear imaging, coronary artery calcium scoring, coronary computed tomographic angiography, percutaneous coronary intervention, coronary artery bypass graft surgery, and transcatheter aortic valve replacement), with disproportionate impacts on older, female, and non-white patients. While in some jurisdictions it appears that these reductions were only temporary, concern remains that the public health response to the pandemic—meant to mitigate morbidity and mortality from acute COVID-19—may have the unintended consequence of increasing CV risk in much larger proportions of the general population.
We therefore undertook an observational study aimed at characterizing trends in the use of important biomarkers of atherosclerotic cardiovascular disease (ASCVD) risk—troponin and low-density lipoprotein cholesterol (LDL-C), the use of invasive cardiac procedures, and major adverse cardiovascular events (MACE) prior to and during the COVID-19 pandemic in the province of Alberta.
Impact on ASCVD Testing
copyright © 2023 MDLearn
Any views expressed above are the author's own and do not necessarily reflect the views of MDLearn.
Chronic Urticaria: That Unrelenting and Nagging Itch &nb...
The Birds and Bees and Allergies: The Forgotten Burden of...
PCSK9 inhibitors: For Which Patient and When?...
Sinking Your Teeth Into ONJ – Debunking Myths and Unde...
Osteoporosis as a chronic disease...
Denosumab 101 Safety, Tolerability and Calcium Monitoring&...
Osteoporosis Management in Primary Care – Anabolic The...
Dyslipidemia Management in Primary Care This blog c...
What advice do I give to my patients who use dietary supplem...
What has changed in terms of Herpes Zoster guidance and why...
What’s New in Insomnia Management and Treatment &ld...
Meningitis B vaccination - a call to action. Why should Men...
Why are we still talking about hypertension? &nbs...
How to incorporate BNP testing into primary care....